Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Phenoxybenzamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenoxybenzamine SCHEMBL202823 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL50729 | 0.99 | ALDH1A1 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL1133740 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL14894820 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL11992656 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL15960915 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL19958436 | 0.85 | ALDH1A1 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11077715 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11682499 | 0.84 | TSHR (0.72) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11684275 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10686 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4608388-A1 | COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES FOR OBESITY AND OTHER DISEASES | STARROCK PHARMA INC. (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025136860-A1 | SOLID DRUG RELEASING BIOABSORBABLE PROSTATE IMPLANT FOR BENIGN PROSTATIC HYPERPLASIA | RESURGE THERAPEUTICS INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250195414-A1 | SOLID DRUG RELEASING BIOABSORBABLE PROSTATE IMPLANT FOR BENIGN PROSTATIC HYPERPLASIA | RESURGE THERAPEUTICS INC. | 2025-06-19 | — | — | US | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4443441-A | Fixation of intraocular lenses | GALIN MILES A | 1984-04-17 | — | — | US | claimed |
| US-4327725-A | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-4310524-A | TCA Composition and method for rapid onset antidepressant therapy | RICHARDSON-MERRELL, INC. (US) | 1982-01-12 | — | — | US | claimed |
| US-4215130-A | Antihypertensive compositions of N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine and N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-benzenemethanamine | RICHARDSON-MERRELL INC. (US) | 1980-07-29 | — | — | US | claimed |
| US-4189492-A | SYNERGISTIC | RICHARDSON-MERRELL INC. (US) | 1980-02-19 | — | — | US | claimed |
| US-4022893-A | Treatment for hypertension | MOYER JOHN H | 1977-05-10 | — | — | US | claimed |